Skip to main content
padlock icon - secure page this page is secure

Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo

Buy Article:

$63.00 + tax (Refund Policy)

Despite the enormous advances in the development of new drugs, the efficacy of current antitumor therapies is still quite limited, most likely because of the high degree of cancer heterogeneity and cell signaling complexity. As a single drug does not necessarily eradicate the cancer, the use of drug combinations has been proposed, and numerous studies have already been conducted to examine the efficacy of this strategy. In the last decade, parthenolide, a plantderived sesquiterpene lactone, was extensively studied and its potential to inhibit cancer cell growth in vitro was well documented. More recently, antitumor effects exerted by parthenolide in combination with various drugs routinely used in cancer treatment have been investigated in several laboratories. In this article studies that are underway in an attempt to improve the anticancer efficacy of chemotherapies through combination strategies involving parthenolide are summarized.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Anticancer drugs; Chemosensitivity; Chemotherapy; Metastasis; NF-κB; Parthenolide

Document Type: Research Article

Publication date: 01 March 2014

More about this publication?
  • The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.

    The scope of Mini-Reviews in Medicinal Chemistry will cover all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies.

    Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more